Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 4, Avril 2016
Page(s) 362 - 369
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163204014
Publié en ligne 2 mai 2016
  1. Pressman D, Korngold L. The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953 ; 6 : 619–623. [CrossRef] [PubMed]
  2. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 2007 ; 34 : 757–778. [CrossRef] [PubMed]
  3. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005 ; 352 : 441–449. [CrossRef] [PubMed]
  4. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993 ; 329 : 459–465. [CrossRef] [PubMed]
  5. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993 ; 329 : 1219–1224. [CrossRef] [PubMed]
  6. Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control 2012 ; 19 : 196–203. [CrossRef] [PubMed]
  7. Tomblyn MB, Katin MJ, Wallner PE. The new golden era for radioimmunotherapy: not just for lymphomas anymore. Cancer Control 2013 ; 20 : 60–71. [CrossRef] [PubMed]
  8. Ketterer N, Delaloye AB, Helg C, et al. Radio-immunothérapie du lymphome folliculaire: un pas vers la guérison ? Bull Cancer 2007 ; 94 : 799–806. [PubMed]
  9. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009 ; 114 : 5444–5453. [CrossRef] [PubMed]
  10. Rose AC, Shenoy PJ, Garrett G, et al. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 2012 ; 12 : 393–399. [CrossRef] [PubMed]
  11. Lindén O, Hindorf C, Cavallin-Ståhl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin’s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005 ; 11 : 5215–5222. [CrossRef] [PubMed]
  12. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007 ; 25 : 5465–5470. [CrossRef] [PubMed]
  13. Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol) 2012 ; 24 : 294–308. [CrossRef] [PubMed]
  14. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013 ; 19 : 5182–5191. [CrossRef] [PubMed]
  15. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010 ; 51 : 311–328. [CrossRef]
  16. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013 ; 369 : 213–223. [CrossRef] [PubMed]
  17. Santoro L, Boutaleb S, Garambois V, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009 ; 50 : 2033–2041. [CrossRef]
  18. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005 ; 46 : (suppl 1) : S4S–12S.
  19. Kitson SL, Cuccurullo V, Moody TS, et al. Radionuclide antibody-conjugates, a targeted therapy towards cancer. Curr Radiopharm 2013 ; 6 : 57–71. [CrossRef] [PubMed]
  20. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005 ; 46 (suppl 1) : S199–S204.
  21. Brechbiel MW. Targeted alpha-therapy: past, present, future ? Dalton Trans 2007 ; 43 : 4918–4928. [CrossRef] [PubMed]
  22. Morgenstern A, Bruchertseifer F, Apostolidis C. Bismuth-213 and actinium-225 - generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm 2012 ; 5 : 221–227. [CrossRef] [PubMed]
  23. Huclier-Markai S, Alliot C, Varmenot N. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Curr Top Med Chem 2012 ; 12 : 2642–2654. [CrossRef] [PubMed]
  24. Pouget J-P, Navarro-Teulon I, Bardiès M, et al. Clinical radioimmunotherapy–the role of radiobiology. Nat Rev Clin Oncol 2011 ; 8 : 720–734. [CrossRef]
  25. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002 ; 100 : 1233–1239. [PubMed]
  26. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res 2013 ; 19 : 530–537. [CrossRef] [PubMed]
  27. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008 ; 49 : 30–38. [CrossRef]
  28. Rosenblat TL, McDevitt MR, Mulford DA, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010 ; 16 : 5303–5311. [CrossRef] [PubMed]
  29. Raja C, Graham P, Abbas Rizvi SM, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007 ; 6 : 846–852. [CrossRef]
  30. Allen BJ, Singla AA, Rizvi SMA, et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 2011 ; 3 : 1041–1050. [CrossRef] [PubMed]
  31. Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2 - a phase I study. J Nucl Med 2009 ; 50 : 1153–1160. [CrossRef]
  32. Cordier D, Forrer F, Bruchertseifer F, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 2010 ; 37 : 1335–1344. [CrossRef] [PubMed]
  33. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1, 4, 7, 10-tetraazacyclododecane-1-glutaric acid-4, 7, 10-triacetic acid-substance p. Clin Cancer Res 2006 ; 12 : 3843–3850. [CrossRef] [PubMed]
  34. Bernier J, Hall EJ, Giaccia A.. Timeline. Radiation oncology: a century of achievements. Nat Rev Cancer 2004 ; 4 : 737–747. [CrossRef] [PubMed]
  35. Vacchelli E, Vitale I, Tartour E, , et al. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013 ; 2 : e25595. [CrossRef] [PubMed]
  36. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004 ; 58 : 862–870. [CrossRef] [PubMed]
  37. Shiraishi K, Ishiwata Y, Nakagawa K, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res 2008 ; 14 : 1159–1166. [CrossRef] [PubMed]
  38. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012 ; 2 : 95. [PubMed]
  39. Keisari Y, Hochman I, Confino H, et al. Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother 2014 ; 63 : 1–9. [CrossRef] [PubMed]
  40. Confino H, Hochman I, Efrati M, et al. Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol Immunother 2015 ; 64 : 191–199. [CrossRef] [PubMed]
  41. Gorin J-B, Menager J, Gouard S, et al. Antitumor immunity induced after α irradiation. Neoplasia 2014 ; 16 : 319–328. [CrossRef] [PubMed]
  42. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007 ; 13 : 54–61. [CrossRef] [PubMed]
  43. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013 ; 31 : 51–72. [CrossRef] [PubMed]
  44. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004 ; 64 : 4328–4337. [CrossRef]
  45. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006 ; 203 : 1259–1271. [CrossRef] [PubMed]
  46. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004 ; 64 : 7985–7994. [CrossRef]
  47. Chakraborty M, Wansley EK, Carrasquillo JA, et al. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 2008 ; 14 : 4241–4249. [CrossRef] [PubMed]
  48. Chakraborty M, Gelbard A, Carrasquillo JA, et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 2008 ; 57 : 1173–1183. [CrossRef] [PubMed]
  49. Milas L, Hunter N, Withers HR. Combination of local irradiation with systemic application of anaerobic corynebacteria in therapy of a murine fibrosarcoma. Cancer Res 1975 ; 35 : 1274–1277.
  50. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 2005 ; 63 : 655–666. [CrossRef] [PubMed]
  51. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013 ; 105 : 256–265. [CrossRef] [PubMed]
  52. Chérel M, Gouard S, Gaschet J, et al. 213Bi Radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 2013 ; 54 : 1597–1604. [CrossRef]
  53. Ménager J, Gorin JB, Maurel C, et al. Combining α-radioimmunotherapy, adoptive T cell therapy to potentiate tumor destruction. PLoS One 2015 ; 10 : e0130249. [CrossRef] [PubMed]
  54. Carpentier AF. Immunothérapie des cancers par oligonucléotides immunostimulants. Med Sci (Paris) 2005 ; 21 : 73–77. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.